Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2176 to 2190 of 2548 results for methods

  1. Phentermine with topiramate for the treatment of obesity and overweight [ID543]

    Discontinued Reference number: GID-TAG439

    Technology appraisal guidance
    Discontinued

  2. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued Reference number: GID-TAG482

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued Reference number: GID-TA10295

    Technology appraisal guidance
    Discontinued

  4. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued Reference number: GID-TAG409

    Technology appraisal guidance
    Discontinued

  5. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued Reference number: GID-TA10180

    Technology appraisal guidance
    Discontinued

  6. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued Reference number: GID-TA10429

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    In development Reference number: GID-TA10747 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

    Technology appraisal guidance
    Discontinued

  9. Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

    Discontinued Reference number: GID-TA10087

    Technology appraisal guidance
    Discontinued

  10. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development Reference number: GID-TA11117 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued Reference number: GID-TA10322

    Technology appraisal guidance
    Discontinued

  13. Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]

    Discontinued Reference number: GID-TA10531

    Technology appraisal guidance
    Discontinued

  14. Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

    Discontinued Reference number: GID-TA10164

    Technology appraisal guidance
    Discontinued

  15. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    Discontinued Reference number: GID-TA10596

    Technology appraisal guidance
    Discontinued